Impact of Ketoflex 12/3 Diet on Early-to-Mid Stage Alzheimer's Progression

Prof. Lutfu Hanoglu, MD60 enrolled

Overview

This study investigates the effects of the Ketoflex 12/3 diet on the clinical progression of early-to-mid stage Alzheimer's disease. The study evaluates cognitive function, metabolic changes, and overall health outcomes in participants following the Ketoflex 12/3 dietary protocol.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

NONE

Enrollment

Conditions

Alzheimer Type Dementia Alzheimer's Disease (AD)

Interventions

Ketoflex 12/3 DietBEHAVIORAL

plant-based ketogenic diet combined with intermittent fasting (12/3)

Eligibility

Sex: ALLMin age: 50 YearsMax age: 85 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age between 50-85 years * Clinical Dementia Rating (CDR) score of 0.5 or 1 * Diagnosis of Alzheimer's disease (AD) according to NINCDS-ADRDA criteria Exclusion Criteria: * Alcohol and/or substance dependence * Diagnosis of chronic renal failure * Diagnosis of another neuropsychiatric disorder * Presence of amalgam dental fillings and/or failure to have them removed following the SMART protocol

Locations (1)

Istanbul Medipol Universitesi

Istanbul, Turkey (Türkiye)

Outcomes

Primary Outcomes

Change in Cognitive Function as Measured by the MMSE Score

Mini-Mental State Examination (MMSE) will be used to assess cognitive function before and after the intervention. The Mini-Mental State Examination (MMSE) is used to assess cognitive function. The total score ranges from 0 to 30, with higher scores indicating better cognitive performance.

Time frame: Baseline and 6 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.